Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free OBI Stock Alerts

Ondine Biomedical (OBI) Competitors

Ondine Biomedical logo
C$14.75 -0.25 (-1.67%)
As of 06/29/2026 03:19 PM Eastern
Compare

OBI vs. VRP, SCLP, BTG, ARIX, and CIR

Should you buy Ondine Biomedical stock or one of its competitors? MarketBeat compares Ondine Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ondine Biomedical include Verona Pharma plc (VRP.L) (VRP), Scancell (SCLP), BTG (BTG), Arix Bioscience (ARIX), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Verona Pharma plc (VRP.L)?

Ondine Biomedical (LON:OBI) and Verona Pharma plc (VRP.L) (LON:VRP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Ondine Biomedical's average media sentiment score of 0.00 equaled Verona Pharma plc (VRP.L)'saverage media sentiment score.

Company Overall Sentiment
Ondine Biomedical Neutral
Verona Pharma plc (VRP.L) Neutral

29.3% of Ondine Biomedical shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Verona Pharma plc (VRP.L) has lower revenue, but higher earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ondine BiomedicalC$2.05M3,740.06-C$424.66K-C$7.00N/A
Verona Pharma plc (VRP.L)N/AN/AN/A-£32.70N/A

Verona Pharma plc (VRP.L) has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Verona Pharma plc (VRP.L)'s return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Ondine Biomedical-1,117.06% -1,411.54% -159.71%
Verona Pharma plc (VRP.L) N/A N/A N/A

Summary

Ondine Biomedical and Verona Pharma plc (VRP.L) tied by winning 4 of the 8 factors compared between the two stocks.

How does Ondine Biomedical compare to Scancell?

Scancell (LON:SCLP) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Scancell has a net margin of -116.98% compared to Ondine Biomedical's net margin of -1,117.06%. Scancell's return on equity of 90.29% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Ondine Biomedical -1,117.06%-1,411.54%-159.71%

Ondine Biomedical has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M38.31-£6.75M-£0.55N/A
Ondine BiomedicalC$2.05M3,740.06-C$424.66K-C$7.00N/A

1.5% of Scancell shares are owned by institutional investors. Comparatively, 29.3% of Ondine Biomedical shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 37.4% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Scancell had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Ondine Biomedical. Scancell's average media sentiment score of 0.50 beat Ondine Biomedical's score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company Overall Sentiment
Scancell Positive
Ondine Biomedical Neutral

Scancell has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.322, meaning that its stock price is 68% less volatile than the broader market.

Summary

Scancell beats Ondine Biomedical on 8 of the 13 factors compared between the two stocks.

How does Ondine Biomedical compare to BTG?

BTG (LON:BTG) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

In the previous week, BTG had 3 more articles in the media than Ondine Biomedical. MarketBeat recorded 3 mentions for BTG and 0 mentions for Ondine Biomedical. BTG's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company Overall Sentiment
BTG Neutral
Ondine Biomedical Neutral

BTG has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. BTG's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
BTGN/A N/A N/A
Ondine Biomedical -1,117.06%-1,411.54%-159.71%

BTG currently has a consensus price target of GBX 160, indicating a potential upside of 35.02%. Given BTG's stronger consensus rating and higher possible upside, equities analysts plainly believe BTG is more favorable than Ondine Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ondine Biomedical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BTG has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£159.40M1.20N/A£6.0019.75
Ondine BiomedicalC$2.05M3,740.06-C$424.66K-C$7.00N/A

19.7% of BTG shares are held by institutional investors. Comparatively, 29.3% of Ondine Biomedical shares are held by institutional investors. 19.7% of BTG shares are held by company insiders. Comparatively, 37.4% of Ondine Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BTG beats Ondine Biomedical on 10 of the 13 factors compared between the two stocks.

How does Ondine Biomedical compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Arix Bioscience has a net margin of 105.64% compared to Ondine Biomedical's net margin of -1,117.06%. Arix Bioscience's return on equity of 6.41% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
Ondine Biomedical -1,117.06%-1,411.54%-159.71%

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 29.3% of Ondine Biomedical shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by company insiders. Comparatively, 37.4% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arix Bioscience has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
Ondine BiomedicalC$2.05M3,740.06-C$424.66K-C$7.00N/A

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company Overall Sentiment
Arix Bioscience Neutral
Ondine Biomedical Neutral

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.322, indicating that its share price is 68% less volatile than the broader market.

Summary

Arix Bioscience beats Ondine Biomedical on 9 of the 10 factors compared between the two stocks.

How does Ondine Biomedical compare to Circassia Group?

Circassia Group (LON:CIR) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Circassia Group has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Circassia Group's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Ondine Biomedical -1,117.06%-1,411.54%-159.71%

In the previous week, Circassia Group's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Ondine Biomedical Neutral

Circassia Group has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Ondine BiomedicalC$2.05M3,740.06-C$424.66K-C$7.00N/A

29.3% of Ondine Biomedical shares are held by institutional investors. 37.4% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Circassia Group beats Ondine Biomedical on 6 of the 8 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OBI vs. The Competition

Export
MetricOndine BiomedicalBiotechnology IndustryMedical SectorLON Exchange
Market CapC$7.66BC$500.10MC$6.84BC$2.79B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-2.113.1726.02366.60
Price / Sales3,740.066,798.66551.0486,600.76
Price / Cash1.9913.1329.0927.87
Price / Book1,708.2390.0311.027.78
Net Income-C$424.66K-C$96.07MC$3.57BC$5.89B
7 Day PerformanceN/A0.64%2.62%0.08%
1 Month Performance-4.10%-0.43%0.95%-1.51%
1 Year Performance3.51%72.60%36.44%65.89%

Ondine Biomedical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBI
Ondine Biomedical
N/AC$14.75
-1.7%		N/A+4.0%C$7.66BC$2.05MN/AN/A
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/AN/A22
SCLP
Scancell
N/AGBX 20.75
flat		N/A+77.8%£215.34M£4.71MN/A51
BTG
BTG
4.3395 of 5 stars		GBX 120
+1.3%		GBX 160
+33.3%		N/A£193.33M£159.40M20.004,690
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel